IMMP | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 20%

Performance

5 Days

-3.33%

1 Month

-17.14%

3 Months

-27.86%

6 Months

-27.50%

1 Year

-45.69%

2 Year

-10.49%

Key data

Stock price

$1.45

P/E Ratio

0.00

DAY RANGE

$1.41 - $1.73

EPS

N/A

52 WEEK RANGE

$1.32 - $3.34

52 WEEK CHANGE

-$42.69

MARKET CAP

382.037 M

YIELD

N/A

SHARES OUTSTANDING

145.261 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

1.25

PUBLIC FLOAT

AVERAGE 10 VOLUME

$122,047

AVERAGE 30 VOLUME

$80,155

Company detail

CEO: Marc Voigt
Region: US
Website: immutep.com
Employees: 0
IPO year: 2011

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Immutep Limited engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer.

Immutep to Participate in Upcoming Investor Conferences

SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences: Jones Healthcare and Technology Innovation Conference Location:Las Vegas, NV Date: Wednesday, 9 April 2025 Time:4:30 pm ET The Citizens Life Sciences ConferenceLocation:New Yo

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with efti will enrol approximately 756 patients at more than 150 clinical sitesTrial results will inform potential marketing approval application in non-small cell lung cancer, one of the largest indications in oncology SYDNEY, AUSTRALIA, March 25, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immun

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

SYDNEY, AUSTRALIA, March 20, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the pivotal TACTI-004 Phase III trial. The poster will be presented at the European Lung Cancer Congress (ELCC) 2025, taking place in Paris, France, from 26-29 March 2025. The Trial in Progress poster includes an overview and study design of the

IMMP - IMMUTEP Ltd

Immutep to Participate in Upcoming Investor Conferences

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025